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Chronic myeloid leukaemia (CML) is a malignant disease of the primitive haematological cell which is 
driven by BCR-ABL1 tyrosine kinase activity.1  Although in recent years CML treatment has been 
drastically improved by the tyrosine kinase inhibitor (TKI) imatinib, at least one-third of patients will 
eventually fail imatinib treatment2, 3 and a significant proportion of these will progress to blast crisis 
(BC). c-Myc is a transcription factor which regulates genes involved in proliferation, cell growth, 
differentiation, and apoptosis. The C-terminal domain of c-Myc has a basic helix-loop-helix leucine 
zipper domain (bHLHZip), necessary for the dimerization with MAX and for DNA binding. c-Myc exerts 
its oncogenic activity via the hetero-dimerization with MAX. Inhibition of c-Myc/MAX interaction has 
been shown to inhibit c-Myc induced cellular transformation. c-Myc is crucial for BCR-ABL1 mediated 
cellular transformation4 and is over-expressed at transformation to blast crisis.5 Furthermore, in CML, 
elevated levels of c-Myc may promote aneuploidy, contributing to disease progression.6, 7  Many 
malignancies, including CML, are associated with inhibition of protein phosphatase 2A (PP2A).8, 9 A 
novel protein inhibitor of PP2A, cancerous inhibitor of PP2A (CIP2A, KIAA1525) is associated with poor 
outcome in many malignancies. In CML, CIP2A protein level at chronic phase diagnosis is a prospective 
biomarker of disease progression in imatinib treated CML patients. Moreover, high CIP2A levels are 
associated with high c-Myc and high BCR-ABL1 tyrosine kinase activity.9 CIP2A acts by impairing PP2A 
activity leading to the stabilisation of c-Myc,10 and this stabilisation is accompanied by 
phosphorylation at serine residue 62 (S62).  CIP2A is an attractive therapeutic target since high levels 
are only found in malignant cells. The structure of CIP2A is unknown, thus specific small molecule 
inhibitors targeting CIP2A have not been developed.  The aim of this work was to inhibit the c-Myc 
using the small molecule inhibitor 10058-F4 which inhibits c-Myc/MAX interaction in order to disrupt 
the CIP2A/c-Myc interaction, and thus attempt to suppress CIP2A indirectly. 
 
K562 and AGS cell lines and newly diagnosed chronic phase patients’ cells were cultured with 60µM 
10058-F4 (Sigma-Aldrich, UK) for 48 hours and changes to the CIP2A/C-Myc pathway were assessed 
by flow cytometry and western blotting methodology as previously described9, 11 and were used for 
the detection of PP2A, PP2A Y307, CIP2A, c-Myc and c-Myc S62. The following antibodies were used: 
Anti-PP2A (Merck Millipore, UK), PP2A Y307 (Epitomics, USA),  CIP2A (Santa Cruz Biotechnology, USA), 
c-Myc (New England Biolabs, UK), c-Myc S62 (Abcam, UK), anti-mouse and anti-rabbit Alex fluor 488 
(Invitrogen, UK).  Levels of pCrKL and CrKL were used as an assay of BCR-ABL1 activity, measured by 
flow cytometry as previously described.11 c-Myc siRNA  (Thermo Scientific. MA, USA) was transfected 
into K562 and CD34+ cells for 72 hours prior to analysis. Cellular proliferation was assessed by a 
bromodeoxyuridine (BrdU) incorporation (Roche Diagnostics, UK). 
 
 
To investigate whether modulating c-Myc could affect CIP2A levels, K562 cells were initially treated 
for 48 hours with 60µM 10058-F4. 10058-F4 significantly decreased both c-Myc (p=0·005, Figure 1A) 
and c-Myc S62 (p=0·003, Figure 1B). Interestingly, c-Myc inhibition led to a decrease in CIP2A (p=0·003, 
Figure 1C), and this was associated with increased PP2A activity (i.e. decreased PP2A Y307) (Figure 1D) 
and decreased BCR-ABL1 tyrosine kinase activity as assessed by decreased pCrKL/CrKL ratio (p=0·003 
Figure 1E). 10058-F4 also significantly reduced the rate of cellular proliferation (p=0.003, Figure 1F). 
Results were also confirmed by Western blot (Figure 1G). 10058-F4 treatment decreased both c-Myc 
and BCR-ABL1 mRNA expression (p=0.002 and p=0.004 respectively, Supplementary Figure 1). No 
effect on CIP2A mRNA expression was observed (data not shown). To investigate whether the 
decrease in CIP2A protein was a direct result of c-Myc reduction or an indirect effect via BCR-ABL1, 
AGS cells (a gastric carcinoma line which is has high CIP2A levels but is BCR-ABL1 negative) were 
treated with 60µM 10058-F4 for 48 hours. Again, c-Myc inhibition resulted in a decrease in CIP2A 
(p=0.001, Figure 1H-I). These data in a BCR-ABL1 negative cell line are in line with the view that the 
effect of 10058-F4 on c-Myc and CIP2A was independent of BCR-ABL1. 
 
The effects of c-Myc inhibition using 10058-F4 were extended to primary CML cells. In patients with a 
high diagnostic CIP2A level, 10058-F4 significantly reduced c-Myc (p=0·03, Figure 2A) and CIP2A 
protein levels (p=0·02, Figure 2C). In those patients with low diagnostic CIP2A level, a reduction in c-
Myc and c-Myc S62 was also observed (Figure 2B), though no effect was seen on the already low CIP2A 
protein level (Figure 2D).  Furthermore, as in the K562 cell line, c-Myc inhibition decreased the BCR-
ABL1 tyrosine kinase activity in both high and low CIP2A patients (Figure 2E-F). Taken together, these 
data in CML cell lines and primary cells suggest that it is possible to target c-Myc inhibition as a 
surrogate for CIP2A inhibition.  
 
We then investigated the role of c-Myc in the CIP2A pathway, using c-Myc siRNA on K562 cells and 
CML CD34+ cells (Figure 3), with similar findings to those seen with c-Myc inhibition by 10058-F4. 
Specifically, Figure 3A and B show significant reduction in c-Myc and c-Myc S62.  Inhibition of c-Myc 
again resulted in an 85% decrease in CIP2A protein (p=0·01, Figure 3C), reactivation of PP2A activity 
and a 60% decrease in BCR-ABL1 tyrosine kinase activity (p=0·01, Figure 3D-E).  
 
Coupled with our previous publication demonstrating that CIP2A siRNA causes a decrease in c-Myc,9 
these data support the notion that CIP2A and c-Myc act to stabilise each other at the protein level by 
mutual protection from proteolytic degradation.  Similarly, inhibition of c-Myc by siRNA in CML CD34+ 
cells resulted in an 80% reduction in CIP2A protein levels (p=0.04, Figure 3F). 
 
Our previous work and that of others has shown that  CIP2A acts to stabilise c-Myc. c-Myc plays a 
critical role in proliferation and cell cycle, and levels are elevated in those patients with a high 
diagnostic CIP2A level.9 In AML cell lines and primary cells 10058-F4 has been shown to inhibit growth, 
induce cell cycle arrest and cause differentiation.12  Herein we have demonstrated that c-Myc 
inhibition by using the small molecule inhibitor 10058-F4 or siRNA leads to a decrease in CIP2A, 
reactivation of PP2A, a decrease in BCR-ABL1 tyrosine kinase activity (as assessed by pCrKL) and 
reduces cellular proliferation. In those patients with a high diagnostic CIP2A level, inhibition of c-Myc 
reduced CIP2A. However, 10058-F4 also reduced BCR-ABL tyrosine kinase activity irrespective of the 
patient’s diagnostic CIP2A level. These data suggest that c-Myc inhibition would be beneficial for all 
CML patients. Recently, it has been shown that there are putative binding sites for c-Myc and MAX 
within the BCR promoter and that c-Myc/MAX hetero-dimers up regulate BCR-ABL1 expression,13 this 
may explain why 10058-F4 treatment reduces BCR-ABL1 tyrosine kinase activity in high and low CIP2A 
patients. Our study has demonstrated that c-Myc inhibition via either 10058-F4 or siRNA results in a 
decrease in CIP2A in K562, mono-nuclear cells and CD34+ cells and suggest that c-Myc inhibition may 
merit further study, especially as it is a surrogate target for CIP2A.  
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Figure legends 
Figure 1. 10058-F4 inhibits c-Myc and reduces CIP2A and BCR-ABL1 tyrosine kinase activity. 
K562 cells were treated with the c-Myc inhibitor 10058-f4 for 48 hours and the CIP2A pathway was 
assessed by flow cytometry and Western blot (n=5). Panel A. c-Myc, Panel B. c-Myc S62. Panel C. CIP2A. 
Panel D PP2A Y307. Panel E pCrkL/CrkL ratio. Panel F BrdU Proliferation assay and Panel G western blot 
analysis. Panel H-I c-Myc inhibition leads to a decrease in CIP2A in AGS cells. (AGS cells are CIP2A 
positive but BCR-ABL1 negative). FACS analysis of the CIP2A and c-Myc following 48h of 10058-f4 
treatment (n=4). 
 
 
 
Figure 2. c-Myc inhibition decreases CIP2A in CML patients 
Diagnostic MNC from high and low CIP2A patients treated with 10058-F4 for 48 hours (n=10). Panel A 
and B shown c-Myc. Panels C and D show CIP2A. Panels E and F pCrKL/CrKL ratio for high and low 
CIP2A patients respectively. G 10058-F4 significantly reduces CIP2A protein levels to a greater degree 
than observed with imatinib in high CIP2A patients 
 
  
 
 
 
Figure 3. c-Myc inhibition leads to a decrease in CIP2A and BCR-ABL1 tyrosine kinase activity. 
Cells were treated with c-Myc siRNA for 72 hours and the CIP2A/c-Myc pathway was assessed. Results 
of K562 cells are shown A-E. Panel A. c-Myc, Panel B. c-Myc S62. Panel C. CIP2A. Panel D PP2A Y307. 
Panel E pCrkL/CrkL ratio (=5). CD34+ selected CML cells were treated with c-Myc siRNA for 72 hours 
prior to analysis (n=4).  With c-Myc siRNA a decrease in CIP2A was observed (panels F-G).  
 
 
 
 
 
  
 
